Gaucher Disease : A Glance from a Medicinal Chemistry Perspective
© 2024 Wiley-VCH GmbH..
Rare diseases are particular pathological conditions affecting a limited number of people and few drugs are known to be effective as therapeutic treatment. Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, belongs to this class of disorders, and it is considered the most common among the Lysosomal Storage Diseases. The two main therapeutic approaches are the Enzyme Replacement Therapy (ERT) and the Substrate Reduction Therapy (SRT). ERT, consisting in replacing the defective enzyme by administering a recombinant enzyme, is effective in alleviating the visceral symptoms, hallmarks of the most common subtype of the disease whereas it has no effects when symptoms involve CNS, since the recombinant protein is unable to significantly cross the Blood Brain Barrier. The SRT strategy involves inhibiting glucosylceramide synthase (GCS), the enzyme responsible for the production of the associated storage molecule. The rational design of new inhibitors of GCS has been hampered by the lack of either the crystal structure of the enzyme or an in-silico model of the active site which could provide important information regarding the interactions of potential inhibitors with the target, but, despite this, interesting results have been obtained and are herein reviewed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
ChemMedChem - (2024) vom: 08. Feb., Seite e202300641 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prencipe, Filippo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gaucher Disease |
|---|
| Anmerkungen: |
Date Revised 08.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/cmdc.202300641 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368189228 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368189228 | ||
| 003 | DE-627 | ||
| 005 | 20240308232457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cmdc.202300641 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM368189228 | ||
| 035 | |a (NLM)38329692 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prencipe, Filippo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gaucher Disease |b A Glance from a Medicinal Chemistry Perspective |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Wiley-VCH GmbH. | ||
| 520 | |a Rare diseases are particular pathological conditions affecting a limited number of people and few drugs are known to be effective as therapeutic treatment. Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, belongs to this class of disorders, and it is considered the most common among the Lysosomal Storage Diseases. The two main therapeutic approaches are the Enzyme Replacement Therapy (ERT) and the Substrate Reduction Therapy (SRT). ERT, consisting in replacing the defective enzyme by administering a recombinant enzyme, is effective in alleviating the visceral symptoms, hallmarks of the most common subtype of the disease whereas it has no effects when symptoms involve CNS, since the recombinant protein is unable to significantly cross the Blood Brain Barrier. The SRT strategy involves inhibiting glucosylceramide synthase (GCS), the enzyme responsible for the production of the associated storage molecule. The rational design of new inhibitors of GCS has been hampered by the lack of either the crystal structure of the enzyme or an in-silico model of the active site which could provide important information regarding the interactions of potential inhibitors with the target, but, despite this, interesting results have been obtained and are herein reviewed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Gaucher Disease | |
| 650 | 4 | |a Glucosylceramide Synthase Inhibitors | |
| 650 | 4 | |a Rare Disease | |
| 650 | 4 | |a Substrate Reduction Therapy | |
| 700 | 1 | |a Barzan, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Savian, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Spalluto, Giampiero |e verfasserin |4 aut | |
| 700 | 1 | |a Carosati, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a De Amici, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Mosconi, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Gianferrara, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Federico, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Da Ros, Tatiana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |d 2006 |g (2024) vom: 08. Feb., Seite e202300641 |w (DE-627)NLM164619577 |x 1860-7187 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:02 |g pages:e202300641 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cmdc.202300641 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 02 |h e202300641 | ||